STAT+: Pharmalittle: We’re reading about Medicaid and sickle cell, pharma CEOs, and more

U.S. policymakers, government officials, and patients are uncertain how Medicaid will cope with the budget strain of new gene therapies for sickle cell disease.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks